Literature DB >> 31378883

LINC01503 promotes cell proliferation, invasion and EMT process in cholangio-carcinoma.

Y-K Qu1, X-S Qu, G Chen, Y Feng, X-L Teng, W-X Liu, Z-X Cheng, J Xu, L-Q Guo.   

Abstract

OBJECTIVE: This work aimed to analyze the relative expression level of long intergenic non-protein coding ribonucleic acid 1503 (LINC01503) in cholangiocarcinoma tissues and cells, and to explore the effects of LINC01503 on cell proliferation, migration and invasion. PATIENTS AND METHODS: Logarithmic growth phase cholangiocarcinoma cells were selected and transfected with Lipofectamine 2000 (si-LINC01503, si-NC). The expression of LINC01503 was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The proliferation of cells was observed by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) assay. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was used to detect cell apoptosis. Transwell assay was used to observe the cell migration and invasion ability.
RESULTS: The expression of LINC01503 was significantly increased in cholangiocarcinoma tissues compared with adjacent tissues (p<0.05), and the up-regulated expression of LINC01503 was associated with lymph node metastasis. Compared with normal bile duct cells (HIBEC), cholangiocarcinoma cells (RBE, QBC939) have higher expression of LINC01503, and si-LINC01503 transfection can effectively reduce the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of cholangiocarcinoma cells.
CONCLUSIONS: LINC01503 is highly expressed in cholangiocarcinoma and can effectively promote the proliferation, migration, invasion and EMT process of cancer cells, and LINC01503 is expected to be a potential biomarker for cholangiocarcinoma.

Entities:  

Year:  2019        PMID: 31378883     DOI: 10.26355/eurrev_201908_18526

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Comprehensive Analysis of LincRNAs in Classical and Basal-Like Subtypes of Pancreatic Cancer.

Authors:  Markus Glaß; Agnes Dorn; Stefan Hüttelmaier; Monika Haemmerle; Tony Gutschner
Journal:  Cancers (Basel)       Date:  2020-07-27       Impact factor: 6.639

2.  Systematic Analysis of the Expression and Prognostic Significance of P4HA1 in Pancreatic Cancer and Construction of a lncRNA-miRNA-P4HA1 Regulatory Axis.

Authors:  Zhili Hu; Fang Song; Yangzhi Hu; Tianyou Liao
Journal:  Biomed Res Int       Date:  2020-12-19       Impact factor: 3.411

3.  GATA1-induced upregulation of LINC01503 promotes carboplatin resistance in ovarian carcinoma by upregulating PD-L1 via sponging miR-766-5p.

Authors:  Yao Li; Yan Zhai; Yuxuan Chen
Journal:  J Ovarian Res       Date:  2021-08-23       Impact factor: 4.234

4.  Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.

Authors:  Mu-Ru Wang; Dan Fang; Mu-Ping Di; Jia-Lun Guan; Ge Wang; Lian Liu; Jia-Qi Sheng; De-An Tian; Pei-Yuan Li
Journal:  Int J Med Sci       Date:  2020-05-18       Impact factor: 3.738

5.  LINC01503/miR-342-3p facilitates malignancy in non-small-cell lung cancer cells via regulating LASP1.

Authors:  Qiming Shen; Yanbin Sun; Shun Xu
Journal:  Respir Res       Date:  2020-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.